Press Room
Press Room 2023Press Releases 2022
Wednesday, 07 December 2022 14:42
In a world first: A severe knee deformity was successfully treated with viable human bone graft -BonoFill- manufactured by Bonus Biogroup, as part of a clinical trial for the treatment of bone deficiencies in limb bones.
Bonus BioGroup (TASE: BONS) is a clinical-stage Israeli biotechnology company, engaged in research and development of biomedical tissue-engineered and cell therapy products. Bonus Biogroup is pleased to announce that a successful knee repair was achieved following the required one-year follow-up period for treating a severe knee deformity (Valgus Knee…
Tuesday, 13 September 2022 14:38
Patent approved in the US grants the Company exclusive right to commercialize its viable human bone graft for the treatment of bone defects representing a market expected to reach $70 Bn in the US alone.
Bonus BioGroup (TASE: BONS) is a clinical-stage Israeli biotechnology company, engaged in research and development of biomedical tissue-engineered and cell therapy products. Bonus BioGroup is pleased to announce that a patent has been issued in the USA [1] that grants Bonus Therapeutics, a wholly-owned subsidiary, the exclusive rights until…
Wednesday, 27 April 2022 05:28
MesenCure, combined with an oncological treatment, ameliorated a life-threatening syndrome
In a preclinical trial carried out in the US, success was demonstrated in treating Cytokine Release Syndrome affecting approximately 41%-78% of cancer patients treated with immunotherapies using Bonus BioGroup's drug product MesenCure Bonus BioGroup (TASE: BONS) is a clinical-stage Israeli biotechnology company, engaged in research and development of biomedical tissue-engineered…
Tuesday, 29 March 2022 05:27
The Company's transition to the new Bonus BioGroup Center, in MATAM Advanced Technologies Park, Haifa, has been completed
Bonus BioGroup (TASE: BONS) is a clinical-stage Israeli biotechnology company, engaged in research and development of biomedical tissue-engineered and cell therapy products. Following an immediate report dated August 29, 2021[1], regarding preparations to increase the manufacturing capacity of the Company's products, Bonus BioGroup is pleased to announce that in March…
Monday, 10 January 2022 05:26
Bonus BioGroup applied to the Israeli Ministry of Health for emergency use authorization of the drug MesenCure for severe Covid-19 patients and submitted results of phase II, multicenter, controlled clinical trial, demonstrating outstanding efficacy
Bonus BioGroup (TASE: BONS) is a clinical-stage Israeli biotechnology company, engaged in research and development of biomedical tissue-engineered and cell therapy products. Bonus BioGroup is pleased to announce that on January 9, 2022, it submitted an application to the Israeli Ministry of Health for an emergency use authorization of MesenCure.…
BONUS BIOGROUP LTD.
info@bonus-bio.com
+972 (0)73 206 7104
Matam Advanced Technology
Park P.O.B 15143 Haifa 31905 Israel
 |
 |
 |
 |
© 2022 Bonus BioGroup Ltd. Created By Netron Israel Ltd